Fluvoxamine Market

2021-2030 Analysis and Review Fluvoxamine Market

Fluvoxamine Market

Fluvoxamine Market by Clinical Application (Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

28-07-2020 REP-HC-5146 120 pages Format

The fluvoxamine market was valued at USD 576.5 Mn by 2019. Rising prevalence of depression and anxiety worldwide primarily drives the fluvoxamine market growth. Additionally, the growing incidence of social anxiety disorder further increases the demand for the fluvoxamine market.

Fluvoxamine Market

Fluvoxamine is categorized as an antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRI). The absorption of fluvoxamine is 53% with the plasma protein binding of 77-80% completely metabolized by the liver having a half-life of 15.6 hours thereby increasing its receptor affinity 100 folds in comparison to other SSRI’s. Fluvoxamine needs to be taken under medical supervision as drug overdose might result in the occurrence of unwanted side effects.

The major segments related to the fluvoxamine market are: 

By Clinical Application (2017–2027; US$ Mn)

Obsessive-Compulsive Disorder

Post Traumatic Stress Disorder


By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy


Geography Segment (2017–2027; US$ Mn)

North America



United Kingdom
Rest of Europe

Asia Pacific

Rest of Asia Pacific

Latin America (LATAM)

Rest of Latin America

Middle East and Africa (MEA)

Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global fluvoxamine market
  • The overall segmentation of the fluvoxamine market, by clinical application, distribution channel, and geography is minutely studied. Obsessive-compulsive disorder and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Growing incidence of depression and anxiety worldwide
  • Significant increase in the clinical trial investigation to understand the mechanism of action of fluvoxamine in the treatment of social anxiety disorder further accentuates the market growth

Report gist?

  • The study of the global fluvoxamine market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of fluvoxamine due to the  rising prevalence of depression and anxiety worldwide
  • The report will benefit researchers actively engaged in performing clinical trial investigation to understand the therapeutic efficacy of fluvoxamine in the treatment of social anxiety disorder across the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to fluvoxamine market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Obsessive-compulsive disorder is spearheading the clinical application segment for the fluvoxamine market. As per the latest research citings presented by the National Institute of Health (NIH), the worldwide prevalence rate associated with obsessive-compulsive disorder is 2% of the general population. The clinical manifestations associated with obsessive-compulsive disorder are persistent uncontrollable thoughts, intrusive images, disturbing impulses, etc. Post-traumatic stress syndrome will be recording exemplary market performance in the near future on account of the effective implementation of treatment guidelines pertaining to depression and anxiety worldwide. As per the information provided by the World Health Organization (WHO), approximately 354 million people survivors of war are suffering from post-traumatic stress syndrome.

Hospital pharmacy is representing the largest market share in the distribution channel segment for the fluvoxamine market. Drug-related adverse events such as loss of appetite, nausea, drowsiness, dry mouth, etc. can be prevented by the precise compounding of fluvoxamine in the presence of a hospital pharmacist. Retail pharmacy is expected to cater to rampant market growth during the forecast period on account of the flourishing generic drugs market and availability of essential medicines at low prices due to government subsidy.

North America is currently dominating the geography segment for the fluvoxamine market. The rising prevalence of depression primarily drives market growth in the region. As per the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately 2.3% of the United States population is reported to be suffering from obsessive-compulsive disorders. Additionally, the existence of developed healthcare infrastructure and domicile of key players such as Apotex Corporation, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Inc., etc. together propel the market growth in the region. Europe is considered as the second-largest regional segment for fluvoxamine market on account of the rising prevalence of post-traumatic stress syndrome in the young adult population residing in the region. Furthermore, the nurturing regulatory environment provided by the European Medical Agency (EMA), for the sale and distribution of the fluvoxamine market. Asia Pacific is anticipated to be the fastest-growing regional segment for the fluvoxamine market owing to the effective implementation of the treatment guidelines pertaining to anxiety and depression.

Select License Type


Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1569

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.